Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26122
Abstract: Kaushansky K, Lichtman MA, Prchal JT, Levi M, Burns LJ, Linch DC, eds. Williams Hematology. 10th ed. New York: McGraw Hill; 2020:721-748. 5. Ho PJ, Wickramasinghe SN, Rees DC, Lee MJ, Eden A, Thein SL.… read more here.
Keywords: hematology; venetoclax idh1; idh1 mutated; acute myeloid ... See more keywords
Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34604
Abstract: Although the clinical outcomes of patients with TP53‐mutated acute myeloid leukemia (AML) are dismal, subsets of patients eligible for curative‐intent therapies may fare better. Because racial disparities are known to affect outcome in hematologic malignancies,… read more here.
Keywords: mutated acute; myeloid leukemia; patients tp53; acute myeloid ... See more keywords
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2054801
Abstract: ABSTRACT Introduction FLT3 inhibitors have been recently introduced as novel treatment targets in patients with FLT3-mutated acute myeloid leukemia (AML). Midostaurin is an oral multikinase inhibitor that targets multiple receptor tyrosine kinases including FLT3 and… read more here.
Keywords: mutated acute; flt3 mutated; acute myeloid; midostaurin ... See more keywords
IDH1R132S‐mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.17199
Abstract: 1. Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. New Engl J Med. 2012;366:1371–81. 2. Kuhlen M, Willasch AM, Dalle… read more here.
Keywords: lymphoblastic leukemia; idh1r132s mutated; acute lymphoblastic; leukaemia ... See more keywords
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of haematology"
DOI: 10.1111/bjh.18887
Abstract: NPM1-mutated acute myeloid leukaemia (NPM1mut AML) represents a mostly favourable/intermediate risk disease that benefits from allogeneic haematopoietic stem cell transplantation (HSCT) in case of measurable residual disease (MRD) relapse or persistence after induction chemotherapy. Although… read more here.
Keywords: mutated acute; npm1 mutated; acute myeloid; molecular failure ... See more keywords
Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
Sign Up to like & getrecommendations! Published in 2022 at "OncoTargets and therapy"
DOI: 10.2147/ott.s265637
Abstract: Abstract TP53 is a key tumor suppressor gene that plays an important role in regulating apoptosis, senescence, and DNA damage repair in response to cellular stress. Although somewhat rare, TP53-mutated AML has been identified as… read more here.
Keywords: mutated acute; myeloid leukemia; targeting tp53; acute myeloid ... See more keywords
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial.
Sign Up to like & getrecommendations! Published in 2021 at "Future oncology"
DOI: 10.2217/fon-2021-0388
Abstract: AMELIORATE is a Phase III, randomized trial aiming to personalize treatment intensity in FLT3-mutated acute myeloid leukemia. The current study provides an early appraisal of chemosensitivity based on peripheral blasts clearance, as assessed by multiparameter flow cytometry, from… read more here.
Keywords: myeloid leukemia; flt3 mutated; based peripheral; acute myeloid ... See more keywords
Targeting TKI-Activated NFKB2-MIF/CXCLs-CXCR2 Signaling Pathways in FLT3 Mutated Acute Myeloid Leukemia Reduced Blast Viability
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10051038
Abstract: Disease relapse is a common cause of treatment failure in FMS-like tyrosine kinase 3 (FLT3) mutated acute myeloid leukemia (AML). In this study, to identify therapeutic targets responsible for the survival and proliferation of leukemic… read more here.
Keywords: mutated acute; myeloid leukemia; flt3 mutated; acute myeloid ... See more keywords
Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14102434
Abstract: Simple Summary TP53-mutated acute myeloid leukemia (AML) represents one of the most informative examples of adverse risk AML. As the currently available therapies have not translated to meaningful advances in the survival of these patients,… read more here.
Keywords: mutated acute; myeloid leukemia; patients tp53; acute myeloid ... See more keywords
How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14184519
Abstract: Simple Summary TP53 mutations are seen in 5–10% of de novo MDS and AML, but 25–40% of therapy-related MDS and AML. Despite the addition of recent drugs to the common regimen and improvement of post… read more here.
Keywords: mutated acute; myeloid leukemia; myeloid; acute myeloid ... See more keywords